| 025-09-10 | 泰坦科技 | 688133 | 20.9 313.5 | 中信建投证券股份 有限公司上海市华 915 (0.6) 1/17 AM (8.8) 11 4.8 | 中信建投证券股份 有限公司上海市华 1110 2125 1/97 -551 18.00 11 -4.00 | eg | | --- | --- | --- | --- | --- | --- | --- | | 交易日期 | 证券商标 | 蓬券代码 | 成交价(元) 成交金额[万元) 成交量(*) 买入营业部 | | 美出营业部 | 是否为专场 | 9月10日，泰坦科技大宗交易成交15万股，成交额313.5万元，占当日总成交额的3.11%，成交价20.9 元，较市场收盘价24.65元折价15.21%。 ...

资金流向方面，主力资金净流出428.73万元，特大单买入125.34万元，占比2.32%，卖出324.71万元，占 比6.01%；大单买入1021.04万元，占比18.88%，卖出1250.40万元，占比23.13%。 截至6月30日，泰坦科技股东户数7718.00，较上期增加12.61%；人均流通股21305股，较上期减少 11.19%。2025年1月-6月，泰坦科技实现营业收入12.19亿元，同比减少12.70%；归母净利润976.52万 元，同比增长91.55%。 分红方面，泰坦科技A股上市后累计派现8662.05万元。近三年，累计派现4010.89万元。 责任编辑：小浪快报 9月9日，泰坦科技盘中下跌2.01%，截至10:52，报24.81元/股，成交5407.10万元，换手率1.31%，总市 值40.80亿元。 泰坦科技今年以来股价涨36.54%，近5个交易日跌1.31%，近20日跌10.88%，近60日涨14.44%。 资料显示，上海泰坦科技股份有限公司位于上海市徐汇区石龙路89号，成立日期2007年10月18日，上市 日期2020年10月30日，公司主营业务涉及为创新研发、生产质控实验室提供科学 ...

《股东大会规则》等法律、法规、规范性文件以及《公司 章程》的相关规定，本次股东大会表决结果未包含本次股东大会会议《通知》中 未列入会议议程的议案，本次股东大会通过的决议合法、有效。 特此公告。 上海泰坦科技股份有限公司董事会 合《公司法》 《证券法》 | 证券代码：688133 证券简称：泰坦科技 公告编号：2025-036 | | | --- | --- | | 上海泰坦科技股份有限公司 | | | 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 | | | 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 | | | 重要内容提示： | | | ? | 本次会议是否有被否决议案：无 | | 一、 | 会议召开和出席情况 | | （一） | 股东大会召开的时间：2025 年 9 月 5 日 | | （二） | 89 股东大会召开的地点：上海市徐汇区石龙路 号 | | （三） | 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 | | 其持有表决权数量的情况： | | | 普通股股东人数 | 84 | | 51,900,777 | 普通股股东所持有表决权数量 ...

（文章来源：证券日报） 证券日报网讯 9月5日晚间，泰坦科技发布公告称，公司2025年第一次临时股东大会审议通过了《关于 公司拟申请注册发行短期融资券的议案》。 ...

证券代码：688133 证券简称：泰坦科技 公告编号：2025-036 上海泰坦科技股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 84 | | --- | --- | | 普通股股东人数 | 84 | | 2、出席会议的股东所持有的表决权数量 | 51,900,777 | | 普通股股东所持有表决权数量 | 51,900,777 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 31.5627 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 31.5627 | （四） 表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 1、表决方式 （一） 股东大会召开的时间：2025 年 9 月 5 日 （二） ...

德恒上海律师事务所 关于 上海泰坦科技股份有限公司 2025年第一次临时股东大会会议的 法律意见 澳恆上海津師事務所 DEHENG SHANGHAI LAW OFFICE 上海市虹口区东大名路 501 号上海白玉兰广场办公楼 23 层 电话：021-5598 9888 传真：021-5598 9898 邮编：200080 德恒上海律师事务所 关于上海泰坦科技股份有限公司 2025 年第一次临时股东大会的法律意见 德恒上海律师事务所 关于 上海泰坦科技股份有限公司 2025年第一次临时股东大会会议的 法律意见 德恒 02G20240317-00002 号 致:上海泰坦科技股份有限公司 德恒上海律师事务所(以下简称"本所")受上海泰坦科技股份有限公司 (以 下简称"泰坦科技"或者"公司"）的委托,指派本所承办律师列席公司于 2025 年 9 月 5 日 (星期五）下午 14:30 在上海市徐汇区石龙路 89 号召开的 2025 年第 一次临时股东大会会议（以下简称"本次股东大会"），就本次股东大会召开的 合法性进行见证并出具本法律意见。 本所承办律师依据本法律意见出具目前已经发生或存在的事实和《中华人民 共和国公 ...

Group 1 - Titan Technology's stock price has declined for eight consecutive days, with a total drop of 19.16%, currently trading at 24.38 CNY per share and a market capitalization of 4.009 billion CNY [1] - The company, established in October 2007 and listed in October 2020, provides integrated technical solutions for scientific services, including research reagents, biological consumables, analytical consumables, laboratory instruments, and specialized chemicals [1] - The revenue composition of Titan Technology includes 25.08% from proprietary specialty chemicals, 20.48% from proprietary high-end reagents, and 15.65% from third-party research instruments and consumables [1] Group 2 - Rongtong Fund holds 1.161 million shares of Titan Technology in its Rongtong Healthcare Industry Mixed Fund A/B, representing 3.28% of the fund's net value, making it the ninth largest holding [2] - During the eight-day decline, the fund has incurred a floating loss of approximately 670.98 thousand CNY [2] - The Rongtong Healthcare Industry Mixed Fund A/B has achieved a year-to-date return of 22.05% and a one-year return of 33.89% [2] Group 3 - The fund managers of Rongtong Healthcare Industry Mixed Fund A/B are Wan Minyuan and Liu Xiyang, with Wan having a tenure of nearly 10 years and a best fund return of 157.54% during his management [3] - Liu Xiyang has been managing the fund for about 1.5 years, with a best fund return of 4.17% during his tenure [3]

Core Viewpoint - Titan Technology reported a decline in total revenue for the first half of 2025, while achieving significant growth in net profit due to strategic adjustments in its business operations [1] Financial Performance - Total revenue for the first half of 2025 was 1.219 billion yuan, a year-on-year decrease of 12.7% [1] - Net profit attributable to shareholders was 9.7652 million yuan, reflecting a year-on-year increase of 91.55% [1] - The diluted earnings per share were not specified, but the significant increase in net profit indicates improved profitability [1] Strategic Adjustments - The decline in revenue was primarily due to the company's decision to adjust its business strategy, which involved relinquishing certain unprofitable or capital-intensive operations [1] - The management emphasized a transformation in the business model, gradually shifting focus towards higher-margin operations [1] Operational Improvements - During the reporting period, the company made notable advancements in production capacity, optimization of the sales team, and new product research and market promotion [1]

Group 1 - Feng Liu's Gao Yi Lin Shan No.1 Fund entered the top ten circulating shareholders of 12 A-shares with a total holding value of approximately 15.445 billion [1] - The fund increased its positions in Angel Yeast, Songjing Co., and Tongrentang, while reducing holdings in Hikvision, Ruifeng New Materials, Zhongju High-tech, Guoci Materials, Dongcheng Pharmaceutical, and Titan Technology [1][5] - Deng Xiaofeng's Gao Yi Xiaofeng No.2 Fund entered the top ten circulating shareholders of 5 A-shares with a total holding value of approximately 6.768 billion, while the Xiaofeng Hongyuan Trust Plan entered 2 A-shares with a total holding value of approximately 3.754 billion [9] Group 2 - Feng Liu's investment philosophy includes three types: investing in well-known good companies, lesser-known good companies, and unknown good companies, each with varying levels of risk and return [6][7] - Deng Xiaofeng emphasizes assessing a company's capacity and space, profit margin based on business characteristics, and the importance of forward-looking investment strategies in rapidly changing industries [18] - The current market trend shows a migration of funds from low-yield deposits to capital markets, driven by the pursuit of higher potential returns [25][27]

Market Overview - The Shanghai Composite Index closed at 3875.53 points, with a change of 0.46% [1] - The total trading volume of A-shares reached 27,776.47 billion yuan [1] Technical Analysis - A total of 63 A-shares experienced a "death cross" where the 5-day moving average fell below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Haitai Biological: 5-day MA at 50.56 yuan, 10-day MA at 51.97 yuan, a difference of -2.72% [1] - Titan Technology: 5-day MA at 27.25 yuan, 10-day MA at 27.85 yuan, a difference of -2.16% [1] - Anglikang: 5-day MA at 50.17 yuan, 10-day MA at 51.27 yuan, a difference of -2.15% [1] Individual Stock Performance - Haitai Biological: Today's change of -2.67%, with a turnover rate of 8.82% [1] - Titan Technology: Today's change of -2.29%, with a turnover rate of 4.22% [1] - Anglikang: Today's change of -0.85%, with a turnover rate of 6.98% [1] - Other stocks with notable performance include: - Rainbow Group: Today's change of -0.13%, with a turnover rate of 3.47% [1] - Wanli Stone: Today's change of -0.51%, with a turnover rate of 2.18% [1] Additional Observations - The market shows a trend of declining stock prices for several companies, indicating potential bearish sentiment [1][2] - The analysis of moving averages suggests a cautious approach for investors focusing on these stocks [1][2]